Pacritinib-d4

(Synonyms: SB1518-d4)
Customer Review

Based on 1 Customer Validation

Pacritinib-d4 (SB1518-d4) is the deuterated-labeled Pacritinib (HY-16379). Pacritinib (SB1518) is an orally active, selective JAK2/FLT3 inhibitor with IC50 values of 23 nM and 22 nM, respectively. Pacritinib inhibits downstream STAT5, ERK1/2, and AKT signaling, and induces Apoptosis and G1 phase arrest. Pacritinib normalizes tumor-induced cytokines/chemokines, and reduces metastasis, tumor growth, shrinkage, migration, liver injury, inflammation, and steatosis. Pacritinib can be used in research on acute myeloid leukemia, myeloproliferative neoplasms, leukemia/lymphoma, GVHD, and alcoholic/non-alcoholic liver fibrosis.

For research use only. We do not sell to patients.

  • Purity : 98.42%
  • Formula: C28H28D4N4O3
  • Molecular Weight:476.60
  • Storage:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs

All JAK Isoforms

More

All STAT Isoforms

More

All ERK Isoforms

More

All Akt Isoforms

More
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00